• MM&M Facebook
  • MM&M Twitter
  • MM&M LinkedIn
  • MM&M Youtube
Advertise
Subscribe
Log in | Register
Medical Marketing & Media
  • News
    • Agencies
    • Data/Analytics
    • Campaigns
    • Commercial
    • Corporate
    • Legal/Regulatory
    • Media
    • Payers
    • Pipeline
    • Technology
    DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

    DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

    Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?

    Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

    Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

    Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

    DTC ads 2017: The good, the bad, and the ugly

    DTC ads 2017: The good, the bad, and the ugly

    We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.

  • Series
    • Data Week
    • Top 100 Agencies
    • Live at Cannes
    • Pharma Report
    • The DTC Report
    • Top 40 Transformers
    Profiles in Creativity

    Profiles in Creativity

    This six-part series, produced by the MM&M Content Lab in partnership with Klick Health, tells personal stories of people using creativity to solve problems in healthcare.

  • Events
    • Live Events
    • Webcasts
    • Leadership Exchanges
  • Videos
  • Resources
    • eBooks
    • Podcasts
    • The Agency Gallery
    • The PMD
    • Whitepapers
  • Careers
    • Women in Healthcare Marketing
    • People Moves
    • Career & Salary Survey Premium
  • Magazine
    • Latest Issue
    • Issue Archive

Newsletters

Opinion

Shortening the drug side-effect list, and five other ways pharma DTC is set to be reformed

By Marc Iskowitz

The cost of curing blindness: Navigating challenges on the road toward curative treatment

By Carolyn Sobczyk, JPA Health Communications

The Cambridge Analytica mess: What does it mean for pharma?

By Richard Watson, VP of Marketing Intelligence, and David Ormesher, CEO, Closerlook

MM&M Articles

  • Popular
  • Emailed
  • Recent
  • PBMs, drugmakers face off over copay accumulators
  • Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'
  • Five things for pharma marketers to know: Thursday, April 19, 2018
  • Five things for pharma marketers to know: Wednesday, April 18, 2018
  • Five things for pharma marketers to know: Tuesday, April 18, 2018
  • PBMs, drugmakers face off over copay accumulators
  • DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?
  • ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.
  • DTC ads 2017: The good, the bad, and the ugly
  • Sandoz signs on to lead launch of Pear's digital therapeutics
  • How Adept Pharma tackled the opioid crisis head on
  • How removing an 's' can change the perception of migraines
  • Five things for pharma marketers to know: Tuesday, April 24, 2018
  • Shortening the drug side-effect list, and five other ways pharma DTC is set to be reformed
  • Five things for pharma marketers to know: Monday, April 23, 2018

Medical Marketing & Media Return To Top

News

  • Agencies
  • Campaigns
  • Commercial
  • Corporate
  • Legal/Regulatory
  • Media
  • Payers
  • Pipeline

Opinion

  • Back Talk
  • Beltway Insider
  • Editor's Desk
  • Partner Forum
  • Private View
  • Viewpoint

User Center

  • Subscribe
  • About us
  • Contact us
  • Media Information
  • Sitemap
  • OBA Ad ChoicesAd Choices

Connect With Us

  • Newsletters
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
Copyright © 2018 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions.